Relaxin for treatment of acute heart failure

Making the case for treating targeted patient profiles

Jaime Hernandez-Montfort, Sonali Arora, Mara T. Slawsky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Patients presenting with acute heart failure (AHF) represent a heterogeneous population with respect to demographics, clinical profiles, and precipitating factors. Despite this, most clinical trials have treated the study population as a homogeneous group in an attempt to achieve adequate statistical power for endpoint analysis. This approach has proven to be of little value in the development of new agents for treatment of AHF. By contrast, the phase III clinical trial of relaxin focused on a subset of AHF patients who were normotensive or hypertensive and who had moderate renal impairment. The study patients, who were primarily from Eastern Europe, represented a population that would be expected to have less genetic variability than the study populations in larger multinational AHF trials. A focused study design targeting specific patient profiles should be considered for future clinical AHF trials that investigate new therapies or compare the effectiveness of existing therapies.

Original languageEnglish (US)
Pages (from-to)198-203
Number of pages6
JournalCurrent Heart Failure Reports
Volume10
Issue number3
DOIs
StatePublished - Sep 1 2013
Externally publishedYes

Fingerprint

Relaxin
Heart Failure
Population
Therapeutics
Precipitating Factors
Eastern Europe
Phase III Clinical Trials
Demography
Clinical Trials
Kidney

Keywords

  • Acute heart failure
  • Blood pressure
  • Clinical trials
  • Relaxin
  • Vasodilator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Emergency Medicine

Cite this

Relaxin for treatment of acute heart failure : Making the case for treating targeted patient profiles. / Hernandez-Montfort, Jaime; Arora, Sonali; Slawsky, Mara T.

In: Current Heart Failure Reports, Vol. 10, No. 3, 01.09.2013, p. 198-203.

Research output: Contribution to journalArticle

Hernandez-Montfort, Jaime ; Arora, Sonali ; Slawsky, Mara T. / Relaxin for treatment of acute heart failure : Making the case for treating targeted patient profiles. In: Current Heart Failure Reports. 2013 ; Vol. 10, No. 3. pp. 198-203.
@article{318c24dce26d41b7bec1aa0494b25c4f,
title = "Relaxin for treatment of acute heart failure: Making the case for treating targeted patient profiles",
abstract = "Patients presenting with acute heart failure (AHF) represent a heterogeneous population with respect to demographics, clinical profiles, and precipitating factors. Despite this, most clinical trials have treated the study population as a homogeneous group in an attempt to achieve adequate statistical power for endpoint analysis. This approach has proven to be of little value in the development of new agents for treatment of AHF. By contrast, the phase III clinical trial of relaxin focused on a subset of AHF patients who were normotensive or hypertensive and who had moderate renal impairment. The study patients, who were primarily from Eastern Europe, represented a population that would be expected to have less genetic variability than the study populations in larger multinational AHF trials. A focused study design targeting specific patient profiles should be considered for future clinical AHF trials that investigate new therapies or compare the effectiveness of existing therapies.",
keywords = "Acute heart failure, Blood pressure, Clinical trials, Relaxin, Vasodilator",
author = "Jaime Hernandez-Montfort and Sonali Arora and Slawsky, {Mara T.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1007/s11897-013-0148-6",
language = "English (US)",
volume = "10",
pages = "198--203",
journal = "Current Heart Failure Reports",
issn = "1546-9530",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Relaxin for treatment of acute heart failure

T2 - Making the case for treating targeted patient profiles

AU - Hernandez-Montfort, Jaime

AU - Arora, Sonali

AU - Slawsky, Mara T.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Patients presenting with acute heart failure (AHF) represent a heterogeneous population with respect to demographics, clinical profiles, and precipitating factors. Despite this, most clinical trials have treated the study population as a homogeneous group in an attempt to achieve adequate statistical power for endpoint analysis. This approach has proven to be of little value in the development of new agents for treatment of AHF. By contrast, the phase III clinical trial of relaxin focused on a subset of AHF patients who were normotensive or hypertensive and who had moderate renal impairment. The study patients, who were primarily from Eastern Europe, represented a population that would be expected to have less genetic variability than the study populations in larger multinational AHF trials. A focused study design targeting specific patient profiles should be considered for future clinical AHF trials that investigate new therapies or compare the effectiveness of existing therapies.

AB - Patients presenting with acute heart failure (AHF) represent a heterogeneous population with respect to demographics, clinical profiles, and precipitating factors. Despite this, most clinical trials have treated the study population as a homogeneous group in an attempt to achieve adequate statistical power for endpoint analysis. This approach has proven to be of little value in the development of new agents for treatment of AHF. By contrast, the phase III clinical trial of relaxin focused on a subset of AHF patients who were normotensive or hypertensive and who had moderate renal impairment. The study patients, who were primarily from Eastern Europe, represented a population that would be expected to have less genetic variability than the study populations in larger multinational AHF trials. A focused study design targeting specific patient profiles should be considered for future clinical AHF trials that investigate new therapies or compare the effectiveness of existing therapies.

KW - Acute heart failure

KW - Blood pressure

KW - Clinical trials

KW - Relaxin

KW - Vasodilator

UR - http://www.scopus.com/inward/record.url?scp=84881478350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881478350&partnerID=8YFLogxK

U2 - 10.1007/s11897-013-0148-6

DO - 10.1007/s11897-013-0148-6

M3 - Article

VL - 10

SP - 198

EP - 203

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

SN - 1546-9530

IS - 3

ER -